Abemaciclib for malignant pleural mesothelioma - Authors' reply
- PMID: 35654055
- DOI: 10.1016/S1470-2045(22)00285-6
Abemaciclib for malignant pleural mesothelioma - Authors' reply
Conflict of interest statement
DAF reports grants from Astex Therapeutics, personal fees from Aldeyra, grants from Boehringer Ingelheim, non-financial support from Clovis, Eli Lilly, and BMS, personal fees from Inventiva and RS Oncology, personal fees, and non-financial support from Roche, grants from MSD and Bayer, personal fees from Atara, Targovax, and Lab21, during the conduct of the study; and grants, personal fees, and non-financial support from BMS, outside the submitted work. NN declares no competing interests.
Comment on
-
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.Lancet Oncol. 2022 Mar;23(3):374-381. doi: 10.1016/S1470-2045(22)00062-6. Epub 2022 Feb 11. Lancet Oncol. 2022. PMID: 35157829 Clinical Trial.
-
Abemaciclib for malignant pleural mesothelioma.Lancet Oncol. 2022 Jun;23(6):e237. doi: 10.1016/S1470-2045(22)00276-5. Lancet Oncol. 2022. PMID: 35654054 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
